In a release, the Company noted event details:

The conference call will be available to interested parties through a live audio Internet broadcast at: http://investors.somaxon.com/eventdetail.cfm. The call will also be archived and accessible at this site for approximately 14 days. Alternatively, callers may participate in the conference call by dialing (800) 762-8908 (domestic) or (480) 629-9774 (international). A telephonic replay will be available for approximately one week following the conclusion of the call by dialing (800) 406-7325 (domestic) or (303) 590-3030 (international), and entering passcode 4173742.

Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area.

((Comments on this story may be sent to newsdesk@closeupmedia.com))

About Somaxon Pharmaceuticals

Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. Somaxon has submitted a New Drug Application for its product candidate, Silenor(R) (doxepin), to the U.S. Food and Drug Administration.

For more information, please visit the company's web site at www.somaxon.com.

SOURCE: Somaxon Pharmaceuticals, Inc.

PondelWilkinson Inc. 
Rob Whetstone, 310-279-5963

About the BIO Investor Forum

The 8th Annual BIO Investor Forum is an international conference featuring late-stage private and emerging public companies. This year's BIO Investor Forum will feature more than 110 presentations by private and publicly traded companies, venture philanthropy organizations, and patient advocacy groups; as well as Therapeutic Workshops(TM) and Business Roundtables with distinguished clinicians, investigators, and investors. Experts hand-selected to speak at this conference will focus on current biotechnology pipeline innovation, and the latest trends in clinical strategy, capital access and creative funding techniques. The Eighth Annual BIO Investor Forum will include healthcare venture and private equity investors, buy-side investors, and research analysts as well as business development executives from leading global pharmaceutical and mature biotechnology companies.

About Somaxon Pharmaceuticals

Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. Somaxon has submitted a New Drug Application for its product candidate, Silenor(R) (doxepin), to the U.S. Food and Drug Administration.

For more information, please visit the company's web site at www.somaxon.com.

SOURCE: Somaxon Pharmaceuticals, Inc.

PondelWilkinson Inc. 
Rob Whetstone, 310-279-5963

About Somaxon Pharmaceuticals, Inc.

Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. Somaxon has submitted a New Drug Application for its product candidate, Silenor(R) (doxepin), to the U.S. Food and Drug Administration.

For more information, please visit the company's web site at www.somaxon.com.

SOURCE: Somaxon Pharmaceuticals, Inc.

PondelWilkinson Inc. 
Rob Whetstone, 310-279-5963